BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/20/2026 7:08:30 AM | Browse: 2 | Download: 7
 |
Received |
|
2026-06-03 08:54 |
|
Peer-Review Started |
|
2026-06-03 08:54 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-23 08:18 |
|
Revised |
|
2026-06-24 08:29 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-07-09 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-09 03:22 |
|
Articles in Press |
|
2026-07-09 03:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-14 00:49 |
|
Publish the Manuscript Online |
|
2026-07-20 07:08 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Methodology vs reality - deciphering cardiovascular safety of proton pump inhibitors in dual antiplatelet therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Elia De Maria |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Elia De Maria, MD, Arrhythmology Lab, Cardiology Unit, Ramazzini Hospital, Via Molinari 1, Carpi 41012, Modena, Italy. e.demaria@inwind.it |
| Key Words |
Proton pump inhibitors; Clopidogrel; Drug-drug interaction; Dual antiplatelet therapy; Percutaneous coronary intervention |
| Core Tip |
The combination of proton pump inhibitor and dual antiplatelet therapy, in patients undergoing percutaneous coronary intervention, has raised concerns because of the risk of drug-drug interaction potentially reducing clopidogrel efficacy and increasing ischemic risk. A recent meta-analysis, by methodically isolating randomized data from observational biases, proved that the increased cardiovascular risk seen in prior literature was a product of patient-level confounding rather than true biological harm and provided reassurance regarding the safety of combining proton pump inhibitors with clopidogrel. |
| Publish Date |
2026-07-20 07:08 |
| Citation |
De Maria E. Letter to the Editor: Methodology vs reality - deciphering cardiovascular safety of proton pump inhibitors in dual antiplatelet therapy. World J Cardiol 2026; 18(7): 123807
|
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i7/123807.htm |
| DOI |
https://doi.org/10.4330/wjc.123807 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
